MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary

por Schmierer, K, Giovannoni, G
Publicado 2021

Axonal damage in the making: Neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter()

por Petzold, A., Tozer, D.J., Schmierer, K.
Publicado 2011

Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK R...

por Giovannoni, G, Brex, PA, Dhiraj, D, Fullarton, J, Freddi, M, Rodgers-Gray, B, Schmierer, K
Publicado 2019

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

por Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., Amor, S.
Publicado 2020

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?

por Mateo-Casas, M., Reyes, S., De Trane, S., Edwards, F., Espasandin, M., Anjorin, G., Baker, D., Schmierer, K., Giovannoni, G.
Publicado 2020

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis

por Allen-Philbey, K., Stennett, A., Begum, T., Johnson, AC., Dobson, R., Giovannoni, G., Gnanapavan, S., Marta, M., Smets, I., Turner, B.P., Baker, D., Mathews, J., Schmierer, K.
Publicado 2021

FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis?

por Campion, T., Smith, R. J. P., Altmann, D. R., Brito, G. C., Turner, B. P., Evanson, J., George, I. C., Sati, P., Reich, D. S., Miquel, M. E., Schmierer, K.
Publicado 2017

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis

por Allen-Philbey, K., Stennett, A., Begum, T., Johnson, A.C., MacDougall, A., Green, S., Dobson, R., Giovannoni, G., Gnanapavan, S., Marta, M., Smets, I., Turner, B.P., Baker, D., Mathews, J., Schmierer, K.
Publicado 2022